ArticleTranslational cancer research2021
The prognosis of giant cell tumor of bone and the vital risk factors that affect its postoperative recurrence: a meta-analysis.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- A systematic review of radiomics in giant cell tumor of bone (GCTB): the potential of analysis on individual radiomics feature for identifying genuine promising imaging biomarkers.Journal of orthopaedic surgery and research · 2023Pooled it
- Evaluation of Morphological and Immunohistochemical Prognostic Parameters in Giant Cell Tumor of Bone.Turk patoloji dergisi · 2026Article
- Soft tissue recurrence in giant cell tumor of Bone: A comprehensive review of pathogenesis, imaging features, and clinical management.Journal of bone oncology · 2025Review
- Clinical pathological characteristics correlation ofTranslational cancer research · 2025Article
- Percutaneous radiofrecuency thermal ablation for management of recurrent bone giant cell tumour.Quantitative imaging in medicine and surgery · 2024Article
- Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1.Human cell · 2024Article
- Giant cell tumor of bone in the pediatric population: a retrospective study highlighting cases of metaphyseal only location and increased local recurrence rates in skeletally immature patients.Skeletal radiology · 2023Article
- Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone.Cancers · 2023Article
- CT-Guided RFA for Management of Surgical Relapses of Giant Cell Tumour of Bone.Cardiovascular and interventional radiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study is to analyze the overall prognosis of giant cell tumor of bone (GCTB) and the risk factors that affect its postoperative recurrence.
methodsThe databases of PubMed, Cochrane, Web of Science, Embase, China national knowledge infrastructure, China Biology Medicine disc, and Wanfang were searched until 20 June 2020. Following patients, intervention, comparator, outcomes, study design (PICOS) guidelines, eligible articles were defined as studies evaluating the overall prognosis of GCTB and the risk factors that affect its postoperative recurrence. The association between five risk factors (surgical methods, whether there is soft tissue invasion, tumor size, p53 expression, vascular endothelial growth factor (VEGF) expression) and the recurrence of GCTB were calculated using fixed-effects or random-effects models. The heterogeneity of the odd ration (OR) and effect size (ES) of each study was quantified using Cochran's Q test and Higgins-I2 statistic. The publication bias was analyzed through the drawing of the funnel diagram.
resultsA total of 10 studies were included in the study. We found that the probability of recurrence of patients who choose simple curettage is 5.75 times that of patients who choose amputation or total resection. Patients with soft tissue invasion are 3.76 times more likely to relapse than non-invasive GCTB. The probability of recurrence of patients with tumors larger than 5 cm is 2.8 times that of patients with tumors smaller than. Patients with positive expression of p53 are 3.82 times more likely to relapse than patients with negative expression. And patients with positive expression of VEGF are 3.82 times more likely to relapse than patients with negative expression.
conclusionsIn conclusion, our analysis of five risk factors can be used to measure the recurrence of GCTB and provide important preoperative recommendations for patients with GCTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.